

Félix Javier Jiménez-Jiménez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6012577/publications.pdf>

Version: 2024-02-01

139
papers

3,962
citations

109321

35
h-index

168389

53
g-index

149
all docs

149
docs citations

149
times ranked

4273
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?. <i>Movement Disorders</i> , 2000, 15, 869-872.	3.9	284
2	Risk-factors for Parkinson's disease: case-control study in the province of CÃ©ceres, Spain. <i>Acta Neurologica Scandinavica</i> , 1994, 89, 164-170.	2.1	138
3	Missense mutations in <i>TENM4</i> , a regulator of axon guidance and central myelination, cause essential tremor. <i>Human Molecular Genetics</i> , 2015, 24, 5677-5686.	2.9	134
4	Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 1998, 105, 497.	2.8	133
5	Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1997, 150, 123-127.	0.6	95
6	Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case-control study. <i>Movement Disorders</i> , 1992, 7, 339-344.	3.9	88
7	Olanzapine can worsen parkinsonism. <i>Neurology</i> , 1998, 50, 1183-1184.	1.1	80
8	Genetics of restless legs syndrome: An update. <i>Sleep Medicine Reviews</i> , 2018, 39, 108-121.	8.5	78
9	Serum levels of Î²-carotene, Î±-carotene and vitamin A in patients with Alzheimer's disease. <i>European Journal of Neurology</i> , 1999, 6, 495-497.	3.3	71
10	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 369.	3.7	68
11	Association between the oxidative polymorphism and early onset of Parkinson's disease*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 291-298.	4.7	65
12	The Role of Nitric Oxide in Neurodegeneration. <i>Drugs and Aging</i> , 1998, 12, 251-259.	2.7	63
13	Influence of age and gender in motor performance in healthy subjects. <i>Journal of the Neurological Sciences</i> , 2011, 302, 72-80.	0.6	62
14	Drug-Induced Myoclonus. <i>CNS Drugs</i> , 2004, 18, 93-104.	5.9	59
15	Vitamin D3 Receptor (VDR) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e65487.	2.5	57
16	Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1996, 141, 39-44.	0.6	56
17	Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. <i>European Journal of Neurology</i> , 2010, 17, 152-159.	3.3	54
18	Environmental Risk Factors for Essential Tremor. <i>European Neurology</i> , 2007, 58, 106-113.	1.4	53

#	ARTICLE	IF	CITATIONS
19	Pharmacological Options for the Treatment of Tourette's Disorder. <i>Drugs</i> , 2001, 61, 2207-2220.	10.9	52
20	An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease. <i>Current Medicinal Chemistry</i> , 2016, 23, 2666-2679.	2.4	51
21	Hypnic Headache Associated With Stage 3 Slow Wave Sleep. <i>Headache</i> , 2000, 40, 753-754.	3.9	49
22	<i>Diamine Oxidase</i>...<sc>rs</sc>10156191 and <sc>rs</sc>2052129 Variants Are Associated With the Risk for Migraine. <i>Headache</i> , 2015, 55, 276-286.	3.9	49
23	Anti-Parkinson's disease drugs and pharmacogenetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 859-874.	3.3	47
24	Genomic and Pharmacogenomic Biomarkers of Parkinson's Disease. <i>Current Drug Metabolism</i> , 2014, 15, 129-181.	1.2	47
25	Slow allotypic variants of the <i>NAT2</i> gene and susceptibility to early-onset Parkinson's disease. <i>Neurology</i> , 1998, 51, 1587-1592.	1.1	46
26	Serum levels of coenzyme Q10 in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2000, 107, 0177-0181.	2.8	46
27	Association between restless legs syndrome and other movement disorders. <i>Neurology</i> , 2019, 92, 948-964.	1.1	45
28	Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 351-354.	2.1	42
29	Clinical features of essential tremor seen in neurology practice: a study of 357 patients. <i>Parkinsonism and Related Disorders</i> , 1997, 3, 187-190.	2.2	41
30	Update on genetics of essential tremor. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 359-371.	2.1	41
31	Acute Effects of 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine in a Model of Rat Designated a Poor Metabolizer of Debrisoquine. <i>Journal of Neurochemistry</i> , 1991, 57, 81-87.	3.9	39
32	LINGO1 and risk for essential tremor: Results of a meta-analysis of rs9652490 and rs11856808. <i>Journal of the Neurological Sciences</i> , 2012, 317, 52-57.	0.6	39
33	An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 298.	3.7	39
34	Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. <i>BMC Neurology</i> , 2010, 10, 95.	1.8	37
35	Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 335.	3.7	37
36	Oxidative polymorphism of debrisoquine in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 289-292.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. <i>Neuroscience Letters</i> , 1998, 249, 65-67.	2.1	34
38	Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <i>Acta Neurologica Scandinavica</i> , 2005, 111, 114-117.	2.1	34
39	Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 795-801.	2.9	33
40	Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 433-448.	3.3	33
41	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Restless Legs Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1448.	1.0	31
42	Neurochemical features of idiopathic restless legs syndrome. <i>Sleep Medicine Reviews</i> , 2019, 45, 70-87.	8.5	31
43	Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. <i>European Journal of Neurology</i> , 2011, 18, 1085-1089.	3.3	30
44	<i>>CYP2C19</i> Polymorphism and Risk for Essential Tremor. <i>European Neurology</i> , 2006, 56, 119-123.	1.4	29
45	Peripheral iron metabolism in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1994, 125, 82-86.	0.6	28
46	Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 436-439.	1.5	28
47	Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. <i>Journal of Neurology</i> , 2011, 258, 203-211.	3.6	28
48	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 306-309.	2.2	28
49	Alcohol consumption and risk for Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2019, 266, 1821-1834.	3.6	27
50	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Multiple Sclerosis. <i>Scientific Reports</i> , 2016, 6, 20830.	3.3	26
51	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, 2336-2347.	3.3	26
52	Possible zoophilia associated with dopaminergic therapy in Parkinson disease. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1178-9.	1.9	26
53	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. <i>Journal of Personalized Medicine</i> , 2020, 10, 217.	2.5	25
54	Sleep disorders in tourette syndrome. <i>Sleep Medicine Reviews</i> , 2020, 53, 101335.	8.5	25

#	ARTICLE	IF	CITATIONS
55	Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. <i>Movement Disorders</i> , 2009, 24, 1910-1915.	3.9	24
56	The Nonsynonymous Thr105Ile Polymorphism of the Histamine N-Methyltransferase is Associated to the Risk of Developing Essential Tremor. <i>NeuroMolecular Medicine</i> , 2008, 10, 356-361.	3.4	23
57	Histamineâ€”Methyl Transferase Polymorphism and Risk for Migraine. <i>Headache</i> , 2008, 48, 1343-1348.	3.9	23
58	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. <i>Frontiers in Genetics</i> , 2012, 3, 273.	2.3	23
59	Association Between Vitamin D Receptor rs731236 (Taq1) Polymorphism and Risk for Restless Legs Syndrome in the Spanish Caucasian Population. <i>Medicine (United States)</i> , 2015, 94, e2125.	1.0	23
60	Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome. <i>Journal of Neural Transmission</i> , 2015, 122, 819-823.	2.8	23
61	Cerebrospinal Fluid Nitrate Levels in Patients with Multiple Sclerosis. <i>European Neurology</i> , 1999, 41, 44-47.	1.4	22
62	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. <i>Neurobiology of Aging</i> , 2013, 34, 2441.e9-2441.e11.	3.1	22
63	The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome. <i>Sleep Medicine</i> , 2014, 15, 266-268.	1.6	22
64	<i>CYP2D6</i> Polymorphism Is Not Associated with Essential Tremor. <i>European Neurology</i> , 1997, 38, 99-104.	1.4	20
65	Current and Future Neuropharmacological Options for the Treatment of Essential Tremor. <i>Current Neuropharmacology</i> , 2020, 18, 518-537.	2.9	20
66	Hemimasticatory Spasm Secondary to Biopercular Syndrome. <i>European Neurology</i> , 2008, 59, 276-279.	1.4	19
67	Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease. <i>Medicine (United States)</i> , 2016, 95, e4147.	1.0	19
68	Alcohol Dehydrogenase 2 Genotype and Allelic Variants Are Not Associated With the Risk for Essential Tremor. <i>Clinical Neuropharmacology</i> , 2007, 30, 196-200.	0.7	19
69	Glutathione-S-transferase P1 polymorphism and risk for essential tremor. <i>European Journal of Neurology</i> , 2008, 15, 234-238.	3.3	18
70	Digital Voice Analysis in Patients With Advanced Parkinsonâ€™s Disease Undergoing Deep Brain Stimulation Therapy. <i>Journal of Voice</i> , 2012, 26, 496-501.	1.5	18
71	<i>Neuronal Nitric Oxide Synthase</i> (<sc><i>nNOS</i></sc>, <sc><i>NOS</i></sc><i>1</i>) rs693534 and rs7977109 Variants and Risk for Migraine. <i>Headache</i> , 2015, 55, 1209-1217.	3.9	18
72	Gamma-aminobutyric acid (GABA) receptors genes polymorphisms and risk for restless legs syndrome. <i>Pharmacogenomics Journal</i> , 2018, 18, 565-577.	2.0	18

#	ARTICLE	IF	CITATIONS
73	Decreased serum selenium concentrations in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 1995, 2, 111-114.	3.3	17
74	Paraoxonase 1 (PON1) polymorphisms and risk for migraine. <i>Journal of Neurology</i> , 2010, 257, 1482-1485.	3.6	17
75	Paraoxonase 1 Polymorphisms Are Not Related with the Risk for Multiple Sclerosis. <i>NeuroMolecular Medicine</i> , 2010, 12, 217-223.	3.4	17
76	H1-MAPT and the Risk for Familial Essential Tremor. <i>PLoS ONE</i> , 2012, 7, e41581.	2.5	17
77	MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome. <i>Journal of Neural Transmission</i> , 2013, 120, 463-467.	2.8	17
78	Association of Essential Tremor With Novel Risk Loci. <i>JAMA Neurology</i> , 2022, 79, 185.	9.0	17
79	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. <i>NeuroMolecular Medicine</i> , 2007, 9, 195-204.	3.4	16
80	Histamineâ€methyl transferase polymorphism and risk for multiple sclerosis. <i>European Journal of Neurology</i> , 2010, 17, 335-338.	3.3	16
81	Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. <i>Sleep Medicine</i> , 2013, 14, 382-384.	1.6	16
82	<i>PITX3</i> and Risk for Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2014, 71, 49-56.	1.4	16
83	Genomic Markers for Essential Tremor. <i>Pharmaceuticals</i> , 2021, 14, 516.	3.8	16
84	Fluctuating penile erection related with levodopa therapy. <i>Neurology</i> , 1999, 52, 210.	1.1	16
85	<i>Gammaâ€Aminobutyric Acid (Gaba) Receptors Rho (Gabrr)</i> Gene Polymorphisms and Risk for Migraine. <i>Headache</i> , 2017, 57, 1118-1135.	3.9	15
86	Sleep disorders in essential tremor: systematic review and meta-analysis. <i>Sleep</i> , 2020, 43, .	1.1	15
87	Biological fluid levels of iron and ironâ€related proteins in Parkinsonâ€s disease: Review and metaâ€analysis. <i>European Journal of Neurology</i> , 2021, 28, 1041-1055.	3.3	15
88	The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2012, 2, .	2.0	15
89	Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. <i>Journal of Neural Transmission</i> , 2017, 124, 285-291.	2.8	14
90	Association Between the rs1229984 Polymorphism in the Alcohol Dehydrogenase 1B Gene and Risk for Restless Legs Syndrome. <i>Sleep</i> , 2017, 40, .	1.1	14

#	ARTICLE	IF	CITATIONS
91	Gamma-aminobutyric acid (GABA) receptors GABRA4, GABRE, and GABRG gene polymorphisms and risk for migraine. <i>Journal of Neural Transmission</i> , 2018, 125, 689-698.	2.8	14
92	Association between the missense alcohol dehydrogenase rs1229984T variant with the risk for Parkinson's disease in women. <i>Journal of Neurology</i> , 2019, 266, 346-352.	3.6	14
93	Association between restless legs syndrome and peripheral neuropathy: A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2021, 28, 2423-2442.	3.3	14
94	Dopamine receptor 3 (DRD3) polymorphism and risk for migraine. <i>European Journal of Neurology</i> , 2010, 17, 1220-1223.	3.3	13
95	SLC1A2 rs3794087 variant and risk for migraine. <i>Journal of the Neurological Sciences</i> , 2014, 338, 92-95.	0.6	13
96	Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2000, 107, 445-449.	2.8	12
97	Extrapyramidal Symptoms Associated with Selective Serotonin Reuptake Inhibitors. <i>CNS Drugs</i> , 2000, 14, 367-379.	5.9	12
98	Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. <i>Pharmacogenomics Journal</i> , 2020, 20, 426-432.	2.0	12
99	Exome-wide rare variant analysis in familial essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 109-116.	2.2	11
100	The Relationship Between Parkinson's Disease and Essential Tremor: Review of Clinical, Epidemiologic, Genetic, Neuroimaging and Neuropathological Data, and Data on the Presence of Cardinal Signs of Parkinsonism in Essential Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 2, 02.	2.0	11
101	Spontaneous intracranial hypotension syndrome treated with a double epidural blood patch. <i>Acta Anaesthesiologica Scandinavica</i> , 2012, 56, 1332-1335.	1.6	10
102	LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. <i>BMC Neurology</i> , 2013, 13, 34.	1.8	10
103	NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis. <i>BMC Neurology</i> , 2014, 14, 87.	1.8	10
104	Neurochemical Features of Rem Sleep Behaviour Disorder. <i>Journal of Personalized Medicine</i> , 2021, 11, 880.	2.5	10
105	Increased serum diamine oxidase activity in nonallergic patients with migraine. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13757.	3.4	10
106	Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor. <i>European Journal of Neurology</i> , 2010, 17, 879-881.	3.3	9
107	The potential of LINGO-1 as a therapeutic target for essential tremor. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1139-1148.	3.4	9
108	Familial Focal Dystonia. <i>European Neurology</i> , 2002, 48, 232-234.	1.4	8

#	ARTICLE	IF	CITATIONS
109	Frequency of CYP2D6 allelic variants in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009, 92, 464-467.	2.1	8
110	A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. <i>Neurological Research</i> , 2016, 38, 880-887.	1.3	8
111	Hypersexuality Possibly Associated With Safinamide. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 635-636.	1.4	8
112	An Update on the Neurochemistry of Essential Tremor. <i>Current Medicinal Chemistry</i> , 2020, 27, 1690-1710.	2.4	8
113	Serum vitamin D, vitamin D receptor and binding protein genes polymorphisms in restless legs syndrome. <i>Journal of Neurology</i> , 2021, 268, 1461-1472.	3.6	7
114	Latest Perspectives in Genetic Risk Factors for Restless Legs Syndrome. <i>European Neurological Review</i> , 2013, 8, 90.	0.5	7
115	Neurochemistry of Idiopathic Restless Legs Syndrome. <i>European Neurological Review</i> , 2015, 10, 35.	0.5	7
116	Serum Trace Elements Concentrations in Patients with Restless Legs Syndrome. <i>Antioxidants</i> , 2022, 11, 272.	5.1	7
117	Motor performance in patients with restless legs syndrome. <i>Movement Disorders</i> , 2009, 24, 1656-1661.	3.9	6
118	<i>NAT2</i> polymorphisms and risk for Parkinsonâ€™s disease: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 937-946.	3.3	6
119	Missense Gamma-Aminobutyric Acid Receptor Polymorphisms Are Associated with Reaction Time, Motor Time, and Ethanol Effects in Vivo. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 10.	3.7	6
120	Endothelial nitric oxide synthase (NOS3) rs2070744 polymorphism and risk for multiple sclerosis. <i>Journal of Neural Transmission</i> , 2020, 127, 1167-1175.	2.8	6
121	Current Treatment Options for REM Sleep Behaviour Disorder. <i>Journal of Personalized Medicine</i> , 2021, 11, 1204.	2.5	6
122	Assessment of Parkinson Disease. <i>Neurologist</i> , 2011, 17, S21-S29.	0.7	5
123	The GSTP1 gene variant rs1695 is not associated with an increased risk of multiple sclerosis. <i>Cellular and Molecular Immunology</i> , 2015, 12, 777-779.	10.5	5
124	Sleep Disorders in Patients with Essential Tremor. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 23.	4.2	5
125	Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 975.	2.5	5
126	MAPT gene rs1052553 variant is not associated with the risk for multiple sclerosis. <i>Human Immunology</i> , 2013, 74, 1705-1708.	2.4	4

#	ARTICLE	IF	CITATIONS
127	Cataplexy Possibly Associated With Lamotrigine. Journal of Clinical Psychopharmacology, 2016, 36, 400-402.	1.4	4
128	DeltaĂ©-aminoĂ©levulinic acid dehydratase gene and essential tremor. European Journal of Clinical Investigation, 2017, 47, 348-356.	3.4	4
129	Common Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphisms are not Related With the Risk for Restless Legs Syndrome. Frontiers in Pharmacology, 2021, 12, 618989.	3.5	3
130	Hereditary Coproporphyrria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia. Tremor and Other Hyperkinetic Movements, 2020, 3, 03.	2.0	3
131	Nicardipine improves motor tics. European Journal of Neurology, 1997, 4, 498-501.	3.3	2
132	Reversible bitemporal hemianopsia related to iatrogenic intracranial hypotension. Journal of Neurology, 2000, 247, 461-462.	3.6	2
133	Concentric visual field defect related to spontaneous intracranial hypotension. International Ophthalmology, 2013, 33, 583-587.	1.4	2
134	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and metaĂ©analysis. Response to letter to the editor by Zheng <i>et al</i>.. European Journal of Neurology, 2021, 28, e13-e14.	3.3	2
135	Treatment Options for Idiopathic Restless Legs Syndrome. European Neurological Review, 2015, 10, 45.	0.5	2
136	Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in ParkinsonĂ©'s disease. Expert Review of Neurotherapeutics, 2002, 2, 427-431.	2.8	1
137	Voice tremor in monozygotic twins. European Journal of Neurology, 2008, 15, e80.	3.3	1
138	Peroneal nerve mononeuropathy associated with herpes zoster. A case report. Neurological Sciences, 2019, 40, 847-850.	1.9	0
139	Vitamin D Receptor and Binding Protein Gene Variants in Patients with Essential Tremor. Molecular Neurobiology, 2022, , 1.	4.0	0